Physician profile
Patricia A Pagnotta
NPI 1316048200
$409,253.43
in general payments reported to CMS, 2019-2025
70 companies · $78K in 2025
The $78K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $68K · 2022: $83K · 2023: $74K · 2024: $106K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Travel and Lodging: $42K · Consulting Fee: $22K · Food and Beverage: $22K · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,591.00 |
| Travel and Lodging | $42,255.39 |
| Consulting Fee | $22,151.75 |
| Food and Beverage | $22,099.29 |
| Education | $204.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $125,985.30 | 2021-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $63,980.12 | 2021-2025 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $44,799.67 | 2021-2025 | Zeposia |
| Biogen, INC. | $44,773.68 | 2021-2025 | Tysabri, Tysabri, Vumerity |
| Genzyme Corporation | $38,045.20 | 2021-2025 | |
| Tg Therapeutics, INC. | $32,130.81 | 2021-2025 | |
| Celgene Corporation | $12,045.15 | 2021-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $7,114.47 | 2021-2025 | Ponvory |
| Mallinckrodt Hospital Products INC. | $6,924.50 | 2021-2023 | Acthar |
| Genentech USA, INC. | $6,158.54 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Horizon Therapeutics Plc | $4,646.39 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $3,837.67 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Merck Kgaa | $3,290.00 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $2,855.02 | 2021-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $2,238.03 | 2021-2025 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,799.44 | 2021-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $889.91 | 2021-2025 | |
| Ucb, INC. | $718.23 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Lundbeck LLC | $535.74 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $470.84 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $412.42 | 2021-2025 | |
| Argenx US, INC. | $365.69 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $358.37 | 2021-2025 | Qelbree |
| Pfizer INC. | $326.46 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $293.39 | 2021-2025 | |
| Csl Behring | $253.82 | 2021-2025 | Hizentra |
| Tanabe Pharma America, INC. | $223.82 | 2021-2025 | Radicava |
| Biohaven Pharmaceuticals, INC. | $219.25 | 2021 | |
| Scilex Pharmaceuticals INC. | $219.02 | 2021-2024 | Ztlido |
| Amneal Pharmaceuticals LLC | $218.99 | 2021-2023 | Rytary |
| Takeda Pharmaceuticals U.S.A., INC. | $206.51 | 2023-2025 | Hyqvia, Gammagard |
| Otsuka America Pharmaceutical, INC. | $192.30 | 2023-2025 | Rexulti, Nuedexta |
| Ge Healthcare | $189.19 | 2021-2025 | |
| Sk Life Science, INC. | $188.45 | 2021-2025 | |
| Genentech, INC. | $176.74 | 2023-2024 | Ocrevus, Enspryng |
| Sandoz INC. | $163.62 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $150.94 | 2021-2023 | Onpattro |
| Neurelis, INC. | $146.41 | 2021-2025 | Valtoco |
| Banner Life Sciences, LLC | $145.94 | 2022-2023 | |
| Catalyst Pharmaceuticals, INC. | $143.60 | 2023-2025 | Fycompa |
| Biohaven Pharmaceutical Holding Company Ltd. | $121.48 | 2022 | |
| Sunovion Pharmaceuticals INC. | $120.37 | 2021-2022 | |
| Grifols USA, LLC | $114.80 | 2021-2023 | Gamunex-C |
| Acadia Pharmaceuticals INC | $91.98 | 2022-2023 | Nuplazid |
| Upsher-Smith Laboratories LLC | $85.48 | 2021-2023 | |
| Harmony Biosciences LLC | $71.66 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $65.68 | 2024-2025 | Ponvory |
| Xeris Pharmaceuticals, INC. | $65.21 | 2022-2025 | Keveyis |
| Kyowa Kirin, INC. | $64.87 | 2022-2024 | Nourianz |
| Sumitomo Pharma America, INC. | $57.59 | 2024 | Aptiom |
| Acorda Therapeutics, INC | $57.35 | 2023 | Ampyra, Inbrija |
| Avadel Cns Pharmaceuticals, LLC | $56.66 | 2024-2025 | Lumryz |
| Averitas Pharma INC. | $52.95 | 2023-2024 | Qutenza |
| Livanova USA, INC. | $51.52 | 2022 | |
| Arbor Pharmaceuticals, INC. | $50.81 | 2021-2022 | |
| Allergan, INC. | $35.48 | 2021 | |
| Merz Pharmaceuticals, LLC | $25.59 | 2022 | |
| Impel Pharmaceuticals INC. | $22.89 | 2022 | |
| Avanir Pharmaceuticals, INC. | $22.73 | 2021 | |
| Cala Health, INC. | $20.91 | 2022 | |
| Avion Pharmaceuticals | $20.17 | 2022 | |
| Merck Sharp & Dohme LLC | $19.49 | 2022 | |
| Abbott Laboratories | $19.37 | 2023 | Proclaim |
| Ani Pharmaceuticals, INC. | $17.99 | 2022 | |
| Medtronic, INC. | $17.81 | 2021 | |
| Inspire Medical Systems, INC. | $15.20 | 2025 | Inspire |
| C2n Diagnostics, LLC | $14.98 | 2025 | Precivityad2 |
| Currax Pharmaceuticals LLC | $14.63 | 2021 | |
| Mdd US Operations, LLC | $13.93 | 2023 | |
| Aucta Pharmaceuticals, INC. | $10.21 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Pagnotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.